Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B2 | P37059 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 5/20 | 0.41 |
| ▸ | PTGES | O14684 | 2/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.40 |
| ▸ | LTC4S | Q16873 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 2/20 | 0.39 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.39 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.39 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.38 |
| ▸ | EPOR | P19235 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2249301 | 0.95 | HSD17B2 (0.48) | HSD17B2NPC1RAB9AFFAR1PTGES | |
| SCHEMBL2247819 | 0.85 | HSD17B2 (0.42) | HSD17B2NPC1RAB9AHSD17B1ACHE | |
| SCHEMBL2242479 | 0.85 | HSD17B2 (0.45) | HSD17B2FFAR1PTGESALOX5LTC4S | |
| SCHEMBL2251011 | 0.84 | FFAR1 (0.43) | HSD17B2FFAR1MAOBHSD17B1 | |
| SCHEMBL4365889 | 0.83 | PTGES (0.45) | HSD17B2NPC1RAB9APTGESALOX5 | |
| SCHEMBL2247349 | 0.82 | HSD17B2 (0.45) | HSD17B2FFAR1PTGESHSD17B1 | |
| SCHEMBL2244759 | 0.82 | HSD17B2 (0.45) | HSD17B2HSD17B1ADAMTS4 | |
| SCHEMBL2244869 | 0.80 | KMT2A (0.41) | HSD17B2NPC1RAB9AHSD17B1ACHE | |
| SCHEMBL2247817 | 0.80 | HSD17B2 (0.42) | HSD17B2FFAR1PTGESALOX5LTC4S | |
| SCHEMBL2253174 | 0.80 | POLB (0.41) | NPC1MAOBADAMTS4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7553873-B2 | Glutamate aggrecanase inhibitors | WYETH (US) | 2009-06-30 | — | — | US | claimed |
| US-20070043066-A1 | Glutamate aggrecanase inhibitors | WYETH (US) | 2007-02-22 | — | — | US | claimed |
| US-7998965-B2 | Glutamate aggrecanase inhibitors | WYETH LLC (US) | 2011-08-16 | — | — | US | disclosed |
| US-20100010012-A1 | GLUTAMATE AGGRECANASE INHIBITORS | WYETH (US) | 2010-01-14 | — | — | US | disclosed |
| US-7553873-B2 | Glutamate aggrecanase inhibitors | WYETH (US) | 2009-06-30 | — | — | US | disclosed |
| US-20070043066-A1 | Glutamate aggrecanase inhibitors | WYETH (US) | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100010012-A1 | GLUTAMATE AGGRECANASE INHIBITORS | ADAMTS5, ADAMTS1, ADAMTS7 | HSD17B2 2502/4885NPC1 3103/4885RAB9A 3609/4885 |
| US-20070043066-A1 | Glutamate aggrecanase inhibitors | ADAMTS5, ADAMTS1, ADAMTS7 | HSD17B2 2502/4885NPC1 3103/4885RAB9A 3609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.